HER2 positive breast carcinoma

This phase II trial tests whether a planned sequence of targeted therapies can eliminate HER2+ metastatic breast cancer and allow patients to stop treatment. The study enrolls people with stage IV HER2+ breast cancer at diagnosis. Participants receive a series of drug combination…

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in people with HER2-positive breast cancer that has spread to 1-3 distant spots (oligo-metastatic). The goal is to shrink or eliminate all cancer with a year of treatment, including local therapies like surgery or radi…

This early-stage trial is testing a vaccine designed to help the immune system recognize and attack HER2-positive breast cancer cells. The vaccine contains two small pieces of the HER2 protein, similar to existing drugs, to trigger an immune response. The study will enroll 36 adu…

This phase 3 trial tests whether adding the targeted drug inavolisib to standard maintenance therapy (Phesgo) can delay cancer growth in people with a specific genetic mutation (PIK3CA) in HER2-positive advanced breast cancer. About 230 participants who have already completed ini…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

Researchers are testing whether adding the drug inavolisib to hormone therapy and the antibody combination trastuzumab plus pertuzumab helps shrink HER2-positive, HR-positive breast tumors before surgery. The trial enrolls 170 patients with early-stage breast cancer that has a PI…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This trial tests whether an experimental drug called HER3-DXd, given alone or with olaparib, can safely shrink tumors in people with advanced breast cancer that has progressed after treatment with T-DXd. The study includes two groups: one receiving the combination, the other rece…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast ca…

This phase 3 trial is testing whether 6 months of HER2-targeted therapy (trastuzumab and pertuzumab) works as well as the standard 12 months for people with early-stage HER2+ breast cancer who had a complete response to initial chemotherapy. About 1,500 participants will be rando…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This trial tests whether adding pyrotinib to the standard pre-surgery drug combination can better shrink HER2-positive breast tumors. Women with early or locally advanced breast cancer receive either the standard combination of pertuzumab, trastuzumab, and docetaxel, or the same …

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This phase 1 trial tests a vaccine made from two HER2 protein fragments in people with advanced breast or esophageal cancers that have spread or cannot be removed. The vaccine aims to train the immune system to recognize and attack HER2-positive tumor cells. Participants receive …

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This study tests a new drug called BL-M07D1, given alone or with pertuzumab, against the standard treatment (taxane + trastuzumab and pertuzumab) for HER2-positive breast cancer before surgery. About 120 women with stage II-III breast cancer will participate. The goal is to see i…

This study tests whether adding zanidatamab to standard chemotherapy can completely eliminate cancer in people with early-stage HER2-positive breast cancer before they have surgery. About 125 participants with stage II or III disease will receive the combination, and doctors will…

This phase 2 trial is testing a drug called zanidatamab in 20 people with early-stage, low-risk HER2-positive breast cancer. The drug is given intravenously, along with hormone therapy pills (letrozole or tamoxifen). The main goal is to see if the cancer disappears completely by …

This phase 2 trial is testing whether using a biomarker test (MammaPrint/BluePrint) to guide treatment choices can improve outcomes for people with early-stage HER2-positive breast cancer. Participants receive standard chemotherapy (paclitaxel, nab-paclitaxel, or docetaxel) combi…

This phase 2 trial tests a personalized approach for people with HER2+ metastatic breast cancer. Doctors use ctDNA blood tests and imaging to decide when to step up or down treatments, including targeted drugs and local therapies, to achieve long-term remission. The goal is to se…

This phase 2 trial is testing two different drug combinations for people with stage I HER2-positive breast cancer after surgery. One group gets trastuzumab emtansine (T-DM1) followed by trastuzumab injections, while the other gets paclitaxel plus trastuzumab. The goal is to see w…

This phase 2 trial is testing whether adding evorpacept to standard trastuzumab and chemotherapy can shrink tumors in people with metastatic HER2-positive breast cancer who have already tried the drug Enhertu. About 120 participants will receive the combination intravenously. The…

This study looks at whether adding a tumor bed boost to standard whole breast radiation after breast-conserving surgery helps women with HER2-positive breast cancer. It will track recurrence, survival, and side effects over seven years. The goal is to see if the extra radiation d…

This phase 3 trial tests an immunotherapy called GLSI-100 in 750 people with HER2-positive breast cancer who are at high risk of their cancer returning after standard treatment. Participants receive a series of injections over a year to help their immune system target and destroy…

This trial is testing an oral form of the chemotherapy drug paclitaxel, given alongside standard anti-HER2 therapies (trastuzumab and pertuzumab), for people with HER2-positive breast cancer. The goal is to find the safest and most effective dose of the oral paclitaxel when used …

This phase II trial is testing whether adding a new oral drug called culmerciclib to standard anti-HER2 therapy and hormone therapy can help maintain control of advanced breast cancer that is both hormone receptor-positive and HER2-positive. The study enrolls women with metastati…

This trial is testing whether a new antibody-drug conjugate called GQ1001, when combined with the oral drug pyrotinib, can safely shrink tumors in people with HER2-positive metastatic breast cancer that has stopped responding to earlier anti-HER2 treatments. The study enrolls abo…

This study tests a new drug, asciminib, combined with trastuzumab in 42 adults with HER2+ breast cancer that has spread to the brain. Participants must have tried at least one prior treatment, including T-DXd and tucatinib. The goal is to see if the combination can shrink brain t…

This study investigates whether patients with HER2-positive metastatic breast cancer who have had their disease controlled for at least two years on anti-HER2 therapy can safely stop that treatment. Participants must also have no detectable cancer DNA in their blood (ctDNA-negati…

This phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells,…

This clinical trial is testing a combination of three drugs—entinostat, pyrotinib, and endocrine therapy—in people with advanced triple-positive breast cancer (cancer that is both hormone receptor-positive and HER2-positive) whose disease has worsened after prior treatment with t…

This phase 2 trial tests a combination of two drugs, SKB264 and inetetamab, in 48 adults with HER2-positive advanced breast cancer that has worsened after prior treatment with T-DXd. The goal is to see if the combo can shrink tumors. Participants receive the drugs intravenously e…

This study will follow 500 people with advanced HER2-positive breast cancer who are receiving pyrotinib (a daily pill) as their first or second treatment. Researchers want to see how well the drug works in real life and whether switching to another targeted therapy (Trastuzumab R…

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

This study tests whether adding the drug olaparib to standard trastuzumab and pertuzumab before surgery can improve outcomes for women aged 60 and older with HER2-positive breast cancer. Participants receive the combination for up to six cycles before surgery, and doctors check h…

This study tests whether giving a precise, high-dose radiation treatment called SBRT to one growing tumor can help people with metastatic breast cancer keep their disease under control. Participants continue their usual drug therapy while receiving SBRT to a single site where can…

This early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…

This study tests whether an artificial intelligence (AI) model can choose the best combination of targeted drugs for women with HER2-positive breast cancer before surgery. About 280 women with early or locally advanced breast cancer will be randomly assigned to either AI-guided t…

This study tests a new drug, CAN016, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 90 participants will receive CAN016 every three wee…

This phase 3 trial tests whether a new drug called GQ1005 works better than the current standard treatment T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. Participants have already been treated with trastuzumab and a taxane. The …

This phase II trial is testing whether patients with early HER2-positive or triple-negative breast cancer who had a complete response to pre-surgery treatment and have no cancer DNA in their blood can safely receive less therapy after surgery. The goal is to reduce side effects w…

This study tests a new drug, trastuzumab rezetecan, for people with HER2-positive early breast cancer whose tumors don't shrink enough after two cycles of standard therapy. About 124 participants will first receive standard treatment, and those with a poor response will switch to…

This study tests whether a combination of targeted drugs (pyrotinib and trastuzumab) plus chemotherapy can completely eliminate HER2-positive breast cancer before surgery. About 182 women with early-stage disease will receive 8 cycles of treatment. The main goal is to see if no c…

This study tests a personalized treatment plan for people with HER2-positive early breast cancer. It compares a newer drug (trastuzumab-deruxtecan) against standard chemotherapy combinations to see which works better and causes fewer side effects. About 702 participants will rece…

This phase 3 trial tests whether a new drug, BL-M07D1, combined with pertuzumab works better than the current standard treatment (docetaxel, trastuzumab, and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. About 596 women aged 18-75 who have …

This pilot study tests whether focused ultrasound, combined with tiny gas bubbles (microbubbles), can help chemotherapy drugs penetrate deeper into HER2-positive breast tumors. Twenty women will receive the ultrasound treatment alongside standard neoadjuvant therapy before surger…

This phase 3 trial is testing a new drug called TQB2930, given with chemotherapy, for people with HER2-positive advanced breast cancer who have already tried at least two prior anti-HER2 treatments. The study compares TQB2930 plus chemo to the standard drug trastuzumab plus chemo…

This phase 3 trial compares an all-oral drug combination (pyrotinib, trastuzumab, and dalpiciclib) against standard chemotherapy plus targeted drugs for advanced HER2-positive breast cancer. About 502 patients who have had at most one prior treatment will be enrolled. The goal is…

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This Phase 2 trial is testing whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can help keep advanced breast cancer from growing. It involves 57 women with HR+/HER2+ metastatic breast cancer whose disease has not worsened after initial treatment. The …

This study tests a drug called patritumab deruxtecan in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. About 81 adults will take part. This is not a cure, but aims to co…

This study tests whether adding surgery and targeted radiation to standard treatment helps people with HER2-positive breast cancer that has spread to up to 5 spots in the body. About 178 adults will be randomly assigned to receive either standard care alone or standard care plus …

This study follows about 300 women with HER2-positive breast cancer that has spread. They are getting a three-drug combination (tucatinib, capecitabine, trastuzumab) as part of their normal care. The goal is to see how well the treatment works and how safe it is in everyday medic…

This study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better…

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…

This phase 2 trial is testing two standard chemotherapy combinations given before surgery for people with HER2-positive early breast cancer. One group gets docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP); the other gets the same without carboplatin (THP). The main goal…

This study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combinat…

This study tests whether taking an oral chemotherapy (paclitaxel) along with a fixed-dose injection of two targeted drugs (pertuzumab and trastuzumab) can eliminate all signs of HER2-positive breast cancer before surgery. About 112 adults with early-stage HER2+ breast cancer will…

This study tests a new way to personalize treatment for people with HER2-positive early-stage breast cancer. A special test (HARPS) analyzes tumor proteins to see if the cancer is likely to respond to certain drugs. The goal is to improve the chance of eliminating all cancer befo…

This study tests whether a new combination of drugs (KN026 plus HB1801 and chemotherapy) works better than the current standard treatment (trastuzumab, pertuzumab, and chemo) for people with HER2-positive breast cancer that has been surgically removed. About 1800 adults with canc…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple proteins on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have not responded to s…

This study tests an experimental drug called SHR-A1811 in people with advanced breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. The trial enrolls 150 adults with HER2-positive or HER2-low breast cancer who have not had radiation …

This phase 3 trial compares a new drug called TQB2102 against a standard chemotherapy combination (TCbHP) for people with HER2-positive breast cancer. The goal is to see if TQB2102 works better at eliminating cancer before surgery. About 544 participants will be randomly assigned…

This study tests the drug trastuzumab deruxtecan (T-DXd) as a first treatment for people with HER2-positive breast cancer that has spread. About 300 participants will take the drug and use digital tools like a smartwatch and pulse oximeter to catch side effects early. The goal is…

This study tests whether a new drug combination (pyrotinib + trastuzumab + docetaxel) works better than the standard combo (pertuzumab + trastuzumab + docetaxel) for shrinking early-stage HER2-positive breast tumors before surgery. Researchers will use a blood test to measure tum…

This study tests whether combining two experimental drugs (HLX22 and HLX87) works better as a first treatment for HER2-positive breast cancer that has returned or spread. About 706 adults with advanced or metastatic breast cancer will participate. The main goals are to see how ma…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer, including HER2-positive and triple-negative types. About 60 adults whose cancer has not responded to standard treatments will receive cells tailored to their t…

This study is for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It tests two drugs together: tucatinib and Doxil. The goal is to see how well the combination shrinks tumors and to track any side effects. About 36 adults will take part.

This study is for people with certain types of breast cancer (HER2-positive or triple-negative) who have a complete response to initial drug therapy. It tests whether they can safely skip surgery and only receive radiation, or skip radiation if surgery shows no cancer left. For a…

This study looks at what happens when people with HER2-positive advanced breast cancer switch between two different targeted therapy combinations after their first treatment stops working. About 600 women will be split into two groups: one switches from HP+chemo to HPy+chemo, the…

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy and targeted therapy can help people with HER2-positive breast cancer. About 53 participants will receive the vaccine alongside standard drugs before surgery. The main goal is to see if…

This phase 3 study tests a new drug called IBI354, given alone or with another drug (pertuzumab), against the current standard treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The trial aims to see if the new combination can delay …

This study is for people with HER2+ breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). It combines targeted drugs (tucatinib, trastuzumab, capecitabine) with radiation to the brain or spine. The goal is to see if this approach helps…

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …

This phase 2 trial is testing a combination of anti-HER2 drugs (trastuzumab emtansine, pertuzumab, and docetaxel) plus hormone therapy (tamoxifen or letrozole) given before and after surgery in 74 Nigerian women with HER2-positive breast cancer. The main goal is to see if the can…

This phase 2 trial is testing whether giving a short course of radiation (SBRT) and two injections of the immunotherapy drug pembrolizumab (Keytruda) before standard chemotherapy can improve outcomes for people with stage 2 or 3 breast cancer. The study aims to see if this combin…

This phase 3 trial is testing whether a new drug called zanidatamab, given with chemotherapy, works better than the current standard treatment (trastuzumab plus chemo) for people with metastatic HER2-positive breast cancer that has worsened after prior therapy. About 550 adults w…

This study tests whether a combination of two targeted drugs (trastuzumab deruxtecan and pertuzumab) can shrink or eliminate HER2-positive breast tumors before surgery. About 50 women with stage II-III breast cancer will receive the drugs for three cycles. If the tumor responds w…

This study is tracking 300 people with HER2-positive or HER2-low breast cancer who are receiving trastuzumab-rezetecan as part of their routine care. Researchers are monitoring side effects and how well the drug works in real-world conditions, not in a strict lab setting. The goa…

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumo…

This phase 2 trial is for people with HER2-positive early breast cancer. After initial standard therapy, those who don't respond well will switch to a stronger combination of newer drugs, including trastuzumab-rezetecan and pyrotinib. The goal is to see if this personalized appro…

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1,450 women aged 18-75 will be randomly assigned to one of the two tr…

This study is tracking 800 Chinese patients with advanced HER2-positive or HER2-low breast cancer who are receiving trastuzumab deruxtecan (T-DXd) in real-world clinics. Researchers want to see how long patients stay on treatment and how well it works outside of clinical trials. …

This early-stage trial tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER2 found on some cancer cells. The study aims to find the safest dose and understand how the drug works…

This phase 2 trial is testing whether women with certain aggressive breast cancers (triple negative or HER2-positive) can safely avoid breast surgery if their tumors disappear completely after a combination of chemotherapy and radiation. The study will enroll 200 women and follow…

This study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. It includes 180 adults whose cancer has spread or cannot be removed and who have already tried at least …

This study tests if the heart drug nebivolol can protect the hearts of women with HER2-positive breast cancer who are receiving trastuzumab, a treatment that can weaken the heart. Researchers will measure heart function and quality of life in 56 participants over several months. …

This study compares two ways of taking the drug pyrotinib for people with HER2-positive advanced breast cancer: taking it every day (continuous) or taking breaks (intermittent). The goal is to see which schedule works better and has fewer side effects. About 186 adults whose canc…

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This study tests a combination of two oral chemotherapy drugs (tucatinib and capecitabine) plus a targeted antibody given directly into the spinal fluid (trastuzumab) for people with HER2-positive breast cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This Phase 3 trial is testing whether extending treatment with the drug pyrotinib (either continuously or in cycles) can help prevent HER2-positive breast cancer from returning. About 488 adults who have already completed initial therapy will be randomly assigned to one of two ex…

This study tests whether taking a daily statin (atorvastatin) can prevent heart damage caused by HER2-targeted therapy in women with early-stage breast cancer. About 60 participants will take the statin alongside their cancer treatment. The goal is to reduce treatment delays or e…

This study tests whether a combination of three drugs—disitamab vedotin, pertuzumab, and toripalimab—can shrink or eliminate HER2-positive breast tumors before surgery. About 40 adults with early-stage breast cancer will receive the drugs intravenously for 18 weeks, then have sur…

This early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, toler…

This Phase 3 trial tests whether a combination of trastuzumab and neratinib works better than the standard trastuzumab and pertuzumab for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial che…

This phase II trial is testing whether combining two drugs—trastuzumab deruxtecan (Enhertu) and durvalumab—given before surgery can eliminate cancer in people with stage III inflammatory breast cancer that has HER2 protein. The study will enroll 63 participants and measure how ma…

This phase 2 trial is testing whether women with HER2-positive or triple-negative breast cancer who have a complete response to chemotherapy can safely skip surgery or radiation. The study will enroll 152 women and monitor them for cancer recurrence, distant spread, or death. The…

This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can lower the risk of cancer coming back in women with HER2-positive breast cancer who still have cancer cells after initial treatment. About 316 women will take pyrotinib daily for a year. Researc…

This study tests a drug called Phesgo, given as a shot under the skin, for women with early-stage HER2-positive breast cancer before they have surgery. About 70 women in Algeria will receive Phesgo along with standard chemotherapy for about 18 weeks. The main goal is to see how m…

This phase 2 trial compares the experimental drug trastuzumab deruxtecan (T-DXd) to standard chemotherapy given before surgery for HER2-positive breast cancer. About 370 participants will receive either T-DXd or standard treatment for three cycles, then further treatment is chose…

Researchers are testing a new PET imaging tracer called 18F-HER2 Affibody to see how well it detects HER2-expressing breast cancer. The study includes 40 adults with confirmed or suspected HER2-positive breast cancer. Participants receive the tracer and then undergo a PET scan. T…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This trial explores whether it is practical to offer routine brain MRI scans to people with HER2-positive metastatic breast cancer. Participants receive a baseline scan and are then randomly assigned to either two more scans over a year or no further scans. The goal is to see if …

This study tests a new type of PET/CT scan that uses a special tracer to see if HER2-positive breast cancer has been completely eliminated after chemotherapy and targeted therapy. The goal is to see if the scan can accurately predict which patients have no cancer left, potentiall…

This study is testing a new, more precise method to measure HER2 levels in leftover tumor tissue from people with HER2-low metastatic breast cancer. The goal is to see if this test can accurately tell who will respond to the drug T-Dxd. Researchers will enroll 200 participants an…

This pilot study tests a special PET/MRI scan that uses a radioactive tracer to find HER2+ breast cancer that has spread to the brain. The scan aims to show whether the cancer cells take up the tracer, which might predict if they will respond to the standard drug trastuzumab deru…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This study is testing whether a special test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one group gets standard treatment without the test results, and the…

This study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone. The study involves 15 women with specific types of breast cancer. I…

This early-phase study aims to see if a special PET scan using 89Zr-trastuzumab can predict how well HER2-positive breast cancer patients will respond to targeted therapy. Ten newly diagnosed adults will receive the imaging agent and undergo PET/MRI scans. The goal is to improve …

This study compares a special contrast-enhanced mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms durin…

This study is testing whether a special whole-body MRI scan can find breast cancer that has come back or spread to other parts of the body earlier than standard methods. Researchers will follow 145 women with aggressive breast cancer types (HER2+ or triple-negative) for five year…

This study is looking at whether a brain MRI can spot cancer that has spread to the brain in people with certain types of breast cancer (triple negative or HER2-positive, stage IIb or III) who have no symptoms. About 100 participants will get a contrast-enhanced brain MRI, give a…

This study is testing whether a special type of scan (PET/MRI) combined with artificial intelligence can accurately tell if HER2-positive breast cancer has been completely eliminated after chemotherapy. Researchers will scan 460 women before, during, and after treatment, then com…

This study tests whether a special exercise program, called PRESIONA, can prevent nerve damage (peripheral neuropathy) caused by chemotherapy in breast cancer patients. The program combines aerobic and strength exercises with blood flow restriction cuffs. Researchers will compare…

This study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …

This study tests whether prolonged overnight fasting, exercise, or both can reduce fatigue in women with advanced breast cancer who are taking CDK4/6 inhibitors with endocrine therapy. Participants will follow a 12-week program of fasting for 12-14 hours overnight, an exercise ro…

This study tests whether megestrol acetate, a drug often used for appetite loss, can prevent or reduce severe tiredness in 132 women with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan (T-DXd). Participants will receive either megestrol acetate …

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study tests whether taking probiotics can prevent severe diarrhea in women with HER2-positive breast cancer who are treated with neratinib. About 308 participants will be randomly assigned to receive either probiotics or a placebo for six weeks, alongside standard diarrhea p…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can …

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …

This study is looking at how hormone treatments for breast cancer, called aromatase inhibitors and tamoxifen, affect blood sugar control and diabetes risk in postmenopausal women. Researchers will compare blood sugar measures in women taking these drugs to healthy women not on tr…

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…

This study is testing whether a special PET/MRI scan using an investigational tracer called [18F]FMISO can help monitor how well chemotherapy works in people with HER2-positive breast cancer. The study involves 25 patients and is for imaging purposes only—it will not change their…

This observational study will follow 1000 people with HER2-positive breast cancer to see how patient and tumor characteristics relate to outcomes like survival and treatment response. Participants are not given any new treatment—researchers simply collect data over time. The goal…

This study looks at why some breast cancer patients get diarrhea from the drug pyrotinib while others don't. Researchers will compare the gut bacteria of 60 patients who develop diarrhea with those who don't. They hope to find specific bacteria that protect against this side effe…

This study looks at whether breast cancer patients on HER2-targeted therapy can safely have fewer heart tests. Currently, patients get heart scans every three months, but most don't change treatment. Researchers will test a personalized schedule based on heart risk, comparing it …

This study collects blood and tumor samples from 230 adults with HER2-positive breast cancer (stages I-IV) who are starting anti-HER2 drugs like trastuzumab. Researchers want to see how the immune system reacts to these treatments. The goal is to learn more, not to test a new the…

This pilot study tests whether a personalized approach to heart imaging can safely reduce the number of echocardiograms women with early-stage breast cancer need during HER2-targeted therapy. The goal is to avoid unnecessary tests while still catching any heart side effects early…

This study aims to find genetic markers that may explain why some HER2-positive breast cancer patients respond well to treatment while others do not, or experience side effects. Researchers will collect blood samples from 9,000 participants and follow them for five years. The goa…

This study takes a small skin sample from breast cancer patients who have received certain chemotherapies. Researchers will turn those skin cells into heart cells in a lab to study why some patients develop heart problems. The goal is to learn more about the link between treatmen…

This study reviews medical records of 600 people with HER2+ or triple-negative breast cancer who had chemotherapy and still had cancer in their lymph nodes. The goal is to see if skipping additional lymph node removal (axillary dissection) leads to more cancer coming back in the …

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…

This study observes 100 people in Korea with advanced HER2-positive breast cancer who take a drug called T-DM1 right after another drug, T-DXd, stops working. Researchers will track how long the cancer stays controlled and how well patients respond. The goal is to learn if this d…

This observational study is following 1,000 people with HER2-positive breast cancer who are receiving a pertuzumab biosimilar as part of their routine care. The goal is to see how doctors are using the drug and how well it works in both neoadjuvant (before surgery) and first-line…

This study is for 500 adults with non-metastatic breast cancer who are about to start treatment like chemotherapy or targeted therapy before surgery. Researchers will collect tumor tissue, blood, and sometimes stool samples and MRI scans during treatment. The goal is to learn why…

This study examines tumor samples from 10 people with HER2-positive breast cancer who still had cancer after standard chemotherapy and trastuzumab. Researchers compare tissue taken before and after treatment to identify markers of resistance. No new treatments are given; the goal…

This study looks at whether it's possible to routinely scan the brains of people with HER2-positive metastatic breast cancer to find cancer spread early. About 69 participants will get a baseline brain MRI, and if no brain tumors are found, they'll be randomly assigned to either …

This study looks at whether educational videos and role-play exercises can help breast cancer patients and their doctors better recognize and manage side effects from certain targeted therapies (antibody drug conjugates). The study involves 30 patients and their clinicians. Resea…

This study is for people with high-risk early breast cancer, including inflammatory breast cancer. Researchers want to see if clusters of tumor cells found in the blood can help predict how well treatment works and the chances of survival. About 130 participants will give blood s…

This study is testing whether a genetic test called HER2DX can help doctors decide on the best treatment for people with early-stage HER2-positive breast cancer. The study will enroll 60 patients and observe how often the test results change the treatment plan recommended by a te…

This study is collecting tumor samples from 1,050 people with early or metastatic breast cancer to analyze fat storage and organelle properties in cancer cells. Researchers aim to create a detailed atlas of these features across different breast cancer subtypes. The goal is to be…

This study looks at whether a very high level of a protein called HER2 (measured by the HER2/CEP17 ratio) affects how well breast cancer patients do after treatment with a combination of two targeted drugs (trastuzumab and pertuzumab). Researchers will review medical records of 3…

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study will look at medical records of 60 Russian patients with advanced HER2-positive breast cancer who have received trastuzumab deruxtecan. Researchers want to see how long the drug keeps cancer from growing and how safe it is. The goal is to understand how well this treat…

This study looks at heart problems in people with HER2+ breast cancer that has spread. All participants are taking trastuzumab-based treatment. The main goal is to see how often heart issues occur, especially in those also taking beta blockers or similar heart medications. A smal…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy given before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after treat…